{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:30:00Z","timestamp":1793863800965,"version":"4.6.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jtauto.2026.100394","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:08:52Z","timestamp":1786547332000},"page":"100394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chimeric antigen receptor T-cell therapy in systemic lupus erythematosus: From B cell depletion to immune reprogramming"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-1825","authenticated-orcid":false,"given":"Wei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtauto.2026.100394_bib1","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/art.27367","article-title":"Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Gouti\u00e8res syndrome","volume":"62","author":"Ramantani","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2026.100394_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejim.2023.06.020","article-title":"Multiple autoimmune syndrome: clinical, immunological and genotypic characterization","volume":"116","author":"Fidalgo","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.jtauto.2026.100394_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2026.107136","article-title":"Machine learning reveals sex-biased platelet-associated molecular signatures in systemic lupus erythematosus","volume":"279","author":"Li","year":"2026","journal-title":"Immunol. Lett."},{"issue":"4","key":"10.1016\/j.jtauto.2026.100394_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102790","article-title":"Basophils in autoimmunity: systemic lupus erythematosus and more?","volume":"20","author":"Poddighe","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.jtauto.2026.100394_bib5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/09612033251371333","article-title":"Epstein-Barr virus infection and its association with systemic lupus erythematosus: systematic review and meta-analysis","volume":"34","author":"Ranjan","year":"2025","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.jtauto.2026.100394_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103648","article-title":"Immunopathogenesis of systemic lupus erythematosus: an update","volume":"23","author":"Arnaud","year":"2024","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.jtauto.2026.100394_bib7","article-title":"Mechanisms underlying gender influence on the clinical course and immunopathogenesis of systemic lupus erythematosus: an explorative review","volume":"16","author":"Varaganti","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jtauto.2026.100394_bib8","article-title":"Diverse roles of NETosis in the pathogenesis of lupus","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2026.100394_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156623","article-title":"The role of innate lymphoid cells in systemic lupus erythematosus","volume":"179","author":"Chen","year":"2024","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/biomedicines12010166","article-title":"Double-Negative T (DNT) cells in patients with systemic lupus erythematosus","volume":"12","author":"Poddighe","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/cei.12703","article-title":"A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sj\u00f6gren's syndrome and systemic lupus erythematosus","volume":"183","author":"Szab\u00f3","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"8","key":"10.1016\/j.jtauto.2026.100394_bib12","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00296-023-05306-5","article-title":"Current treatment of systemic lupus erythematosus: a clinician's perspective","volume":"43","author":"Katarzyna","year":"2023","journal-title":"Rheumatol. Int."},{"issue":"23","key":"10.1016\/j.jtauto.2026.100394_bib13","first-page":"1879","article-title":"Chinese systemic lupus Erythematosus research consortium, rheumatology branch of the Chinese Medical association. Chinese Guidelines for the diagnosis and treatment of systemic lupus Erythematosus (2025 edition)","volume":"105","year":"2025","journal-title":"Chin. Med. J."},{"issue":"2","key":"10.1016\/j.jtauto.2026.100394_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/acr.24464","article-title":"Prevalence, predictors, and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: a systematic review","volume":"74","author":"Yang","year":"2022","journal-title":"Arthritis Care Res."},{"issue":"9","key":"10.1016\/j.jtauto.2026.100394_bib15","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/pharmaceutics16091176","article-title":"Biologics in systemic lupus erythematosus: recent evolutions and benefits","volume":"16","author":"Kundnani","year":"2024","journal-title":"Pharmaceutics"},{"issue":"868","key":"10.1016\/j.jtauto.2026.100394_bib16","first-page":"688","article-title":"Th\u00e9rapie cellulaire CAR-T dans le traitement des maladies auto-immunes [CAR-T therapy for autoimmune diseases]","volume":"20","author":"Alcaraz-Serna","year":"2024","journal-title":"Rev. Med. Suisse"},{"issue":"10416","key":"10.1016\/j.jtauto.2026.100394_bib17","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jtauto.2026.100394_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jtauto.2026.100394_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","article-title":"B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies","volume":"47","author":"Canny","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.jtauto.2026.100394_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9","key":"10.1016\/j.jtauto.2026.100394_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.jtauto.2026.100394_bib22","first-page":"1409","article-title":"Overexpression of Fc\u03b3RIIB regulates downstream protein phosphorylation and suppresses B cell activation to ameliorate systemic lupus erythematosus","volume":"46","author":"Sheng","year":"2020","journal-title":"Int. J. Mol. Med."},{"issue":"8","key":"10.1016\/j.jtauto.2026.100394_bib23","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jtauto.2026.100394_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103369","article-title":"CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy","volume":"151","author":"Uppin","year":"2025","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.jtauto.2026.100394_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41573-025-01349-4","article-title":"Roads and detours for CAR T cell therapy in autoimmune diseases","volume":"25","author":"Avouac","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.jtauto.2026.100394_bib26","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jaci.2022.08.003","article-title":"Autoimmune Diseases working party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). New insights in systemic lupus erythematosus: from regulatory T cells to CAR-T-cell strategies","volume":"150","author":"Doglio","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jtauto.2026.100394_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-323-90242-7.00015-8","article-title":"Immune reconstitution in rheumatic disease patients after autologous hematopoietic stem cell transplantation","volume":"202","author":"Santana-Gon\u00e7alves","year":"2024","journal-title":"Handb. Clin. Neurol."},{"issue":"12","key":"10.1016\/j.jtauto.2026.100394_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.jtauto.2026.100394_bib29","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.molmed.2025.12.006","article-title":"Mapping clinical CAR-T cells: insights from scRNA-seq","volume":"32","author":"Meehl","year":"2026","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jtauto.2026.100394_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/art.70117","article-title":"Dual-Targeting BCMA-CD19 CAR-T cell therapy in systemic lupus erythematosus: single-cell and immune repertoire analysis reveals mechanisms of immune reconstitution","author":"He","year":"2026","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.jtauto.2026.100394_bib31","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jtauto.2026.100394_bib32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2026.100394_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103489","article-title":"Preliminary safety and efficacy of relmacabtagene autoleucel (Relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study","volume":"157","author":"Wang","year":"2025","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jtauto.2026.100394_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (Relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.jtauto.2026.100394_bib35","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jtauto.2026.100394_bib36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00393-025-01705-0","article-title":"Langzeitverlauf von Effizienz und Sicherheit der CD19-CAR T-Zell-Therapie beim systemischen Lupus erythematodes [Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus]","volume":"84","author":"Taubmann","year":"2025","journal-title":"Z. Rheumatol."},{"issue":"8","key":"10.1016\/j.jtauto.2026.100394_bib37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Res."},{"issue":"10","key":"10.1016\/j.jtauto.2026.100394_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100749","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","volume":"6","author":"Wang","year":"2025","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.jtauto.2026.100394_bib39","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41591-025-04191-8","article-title":"Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases","volume":"32","author":"Becilli","year":"2026","journal-title":"Nat Med."},{"issue":"19","key":"10.1016\/j.jtauto.2026.100394_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910845","article-title":"B-Cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus","volume":"25","author":"Martin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.jtauto.2026.100394_bib41","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","article-title":"BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis","volume":"84","author":"Hu","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jtauto.2026.100394_bib42","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jtauto.2026.100394_bib43","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"issue":"10","key":"10.1016\/j.jtauto.2026.100394_bib44","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jtauto.2026.100394_bib45","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s12015-025-10923-7","article-title":"Validation of BCMA-CD19 compound CAR-T therapy in SLE overlap syndrome: over 1.5-Year Follow-Up","volume":"21","author":"Wang","year":"2025","journal-title":"Stem Cell Rev. Rep."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-026-01779-6","article-title":"BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial","volume":"19","author":"Hong","year":"2026","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.jtauto.2026.100394_bib47","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/1573397119666230214103044","article-title":"Autologous CD19-Targeted chimeric antigen receptor (CAR)T-Cells as the future of systemic lupus Erythematosus treatment","volume":"19","author":"Kambayana","year":"2023","journal-title":"Curr. Rheumatol. Rev."},{"issue":"11","key":"10.1016\/j.jtauto.2026.100394_bib48","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1002\/eji.201242629","article-title":"Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model","volume":"42","author":"W\u00f6hner","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jtauto.2026.100394_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1502298","article-title":"The advent of chimeric antigen receptor T cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment","volume":"15","author":"Guo","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ekir.2025.10.008","article-title":"Bicistronic-CD19\/22 chimeric antigen receptor T-Cell therapy for childhood refractory Lupus nephritis","volume":"11","author":"Mao","year":"2025","journal-title":"Kidney Int. Rep."},{"issue":"9","key":"10.1016\/j.jtauto.2026.100394_bib51","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/cancers17091454","article-title":"Emerging role of chimeric antigen receptor-natural killer cells for the treatment of hematologic malignancies","volume":"17","author":"Testa","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jtauto.2026.100394_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000547531","article-title":"Beyond CAR-T: the rise of CAR-NK\/T cells for haematological cancer","volume":"149","author":"Noorafrooz","year":"2026","journal-title":"Acta Haematol."},{"issue":"11","key":"10.1016\/j.jtauto.2026.100394_bib53","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ard.2025.07.028","article-title":"Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus","volume":"84","author":"Fu","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"10522","key":"10.1016\/j.jtauto.2026.100394_bib54","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","article-title":"Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China","volume":"406","author":"Gao","year":"2026","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jtauto.2026.100394_bib55","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40291-024-00730-0","article-title":"The future of CAR T therapeutics to treat autoimmune disorders","volume":"28","author":"Pecher","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.jtauto.2026.100394_bib56","article-title":"Overcoming antigen loss in CAR T therapy with V\u03b39V\u03b42 CAR T-cells","volume":"26","author":"Velasco","year":"2025","journal-title":"Immunooncol Technol"},{"issue":"8","key":"10.1016\/j.jtauto.2026.100394_bib57","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.7150\/thno.125983","article-title":"CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells","volume":"16","author":"Wang","year":"2026","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100176","article-title":"Tisagenlecleucel in combination with ibrutinib in adults with relapsed and\/or refractory large B-cell lymphomas","volume":"3","author":"Chavez","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"14","key":"10.1016\/j.jtauto.2026.100394_bib59","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136185","article-title":"CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD","volume":"5","author":"Imura","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtauto.2026.100394_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib61","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005122","article-title":"Association of peripheral CD8+ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus","volume":"11","author":"Fujita","year":"2025","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib63","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-022-00359-3","article-title":"Donor T cells for CAR T cell therapy","volume":"10","author":"Tang","year":"2022","journal-title":"Biomark. Res."},{"issue":"15","key":"10.1016\/j.jtauto.2026.100394_bib64","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/1750743X.2025.2572963","article-title":"Allogeneic CAR-T cell therapy in autoimmune diseases","volume":"17","author":"Ma","year":"2025","journal-title":"Immunotherapy"},{"issue":"15","key":"10.1016\/j.jtauto.2026.100394_bib65","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-Cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","article-title":"Autologous, allogeneic, in vivo CAR for autoimmune diseases","volume":"47","author":"Li","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"issue":"10437","key":"10.1016\/j.jtauto.2026.100394_bib69","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jtauto.2026.100394_bib70","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2403743","article-title":"Anti-CD19 CAR T cells in refractory immune Thrombocytopenia of SLE","volume":"391","author":"Li","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"10468","key":"10.1016\/j.jtauto.2026.100394_bib72","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/S0140-6736(24)02265-7","article-title":"Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells","volume":"404","author":"Hagen","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jtauto.2026.100394_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jtauto.2026.100394_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001742","article-title":"Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis","volume":"12","author":"Gerber","year":"2025","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1016\/j.jtauto.2026.100394_bib67","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00210-025-04425-z","article-title":"CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies","volume":"399","author":"Sayed","year":"2026","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jtauto.2026.100394_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152786","article-title":"CAR T-cell therapy in SLE: a systematic review","volume":"74","author":"Nordmann-Gomes","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jtauto.2026.100394_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101039","article-title":"Anti-CD19 CAR T cell therapy for refractory SLE-ITP","volume":"7","author":"Li","year":"2026","journal-title":"Med"},{"issue":"9","key":"10.1016\/j.jtauto.2026.100394_bib73","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"M\u00fcller","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtauto.2026.100394_bib74","first-page":"1119","article-title":"[Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy]","volume":"56","author":"Wang","year":"2024","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"5","key":"10.1016\/j.jtauto.2026.100394_bib76","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12519-025-00913-7","article-title":"Innovative therapies for childhood-onset systemic lupus erythematosus","volume":"21","author":"Poddighe","year":"2025","journal-title":"World J Pediatr"}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258990902600047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258990902600047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:46:30Z","timestamp":1793861190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258990902600047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":77,"alternative-id":["S258990902600047X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2026.100394","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T-cell therapy in systemic lupus erythematosus: From B cell depletion to immune reprogramming","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2026.100394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100394"}}